NCT01855048View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 6, 2013

Primary Completion Date

February 7, 2014

Study Completion Date

February 7, 2014

Conditions
Healthy VolunteersAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus Aureus
Interventions
BIOLOGICAL

N-Rephasin® SAL200

continuous intravenous infusion over 60 minutes

OTHER

INT200-Placebo

Formulation buffer for continuous intravenous infusion over 60 minutes

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Intron Biotechnology, Inc.

INDUSTRY